Generated by AI
Cassava Sciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders. Its primary product candidate, simufilam, is an investigational oral small molecule drug currently advancing in preclinical studies for tuberous sclerosis complex (TSC)-related epilepsy, where it has shown reductions in seizure activity in mouse models. The company previously explored simufilam and the diagnostic SavaDx for Alzheimer's disease but discontinued that program following Phase 3 trial results. Cassava Sciences Inc. conducts research emphasizing unmet needs in neurodegenerative and neurological conditions, supported by a team of experienced professionals in neuroscience, clinical development, and regulatory affairs. Headquartered in Austin, Texas since its name change in 2019, and founded in 1998, the company maintains a streamlined operation dedicated to advancing its pipeline through proof-of-concept studies and strategic hires in epilepsy therapeutics.
Website6801 N. Capital of Texas Highway
Austin, TX, 78731
United States
The latest articles about SAVA.
AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapi...
– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hol...
Summary of Apr 8's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigatorsOngoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a bio
Summary of Sep 23's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Investors talking about SAVA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.